Thursday, September 13, 2018 4:43:34 PM
A couple of new assets will be moved into the pipeline over the next few months from the lab. OXB will talk about those soon. These match the direction of existing clients. Maybe brain (axovant) liver ( Sanofi ) etc. ?
Revenue potential looks fab. Substantial growth.
Hope to be a part of Novartis` drug progression beyond the 2nd CAR T.
Pipeline has never looked healthier in term of feasibility studies for new customers.
Enormous growth opportunities.
Mentioned process C
3 clean rooms working flat out. Bullish about 2nd half revenue.
TRiP improves by x 10 so looking at out-licensing deal of up front and royalty. Does lenti and AAV. Good IP too.
Working on an awful lot of feasibility so expect further deals over next 12 months.
Manufacturing process is difficult so a real barrier to entry for others.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM